logo

Aikido Pharma Inc. (AIKI)



Trade AIKI now with
  Date
  Headline
8/6/2021 10:02:11 AM AIkido Updates On Use Of Machine Learning In Drug Development Program
7/16/2021 10:17:06 AM AIkido Says Scientists Identified 4 Lead Compounds That Block Influenza, Coronavirus, And Ebolavirus Replication
6/23/2021 10:03:16 AM AIkido Files Patent Application For Use Of Ketamine To Treat Alzheimer's Disease
5/20/2021 9:38:42 AM AIkido Pharma : Phase 1 Data To Be Presented At American Society Of Clinical Oncology Annual Meeting
5/11/2021 9:06:18 AM AIkido Pharma Reports Cash Balance Of $102 Mln Or About $1.15 Per Share As Of March 31st
4/26/2021 9:07:14 AM AIkido Pharma Names Matthew Frieman Scientific Advisory Board
4/22/2021 9:12:50 AM AIkido Pharma Announces Withdrawal Of S-1 Registration Statement
4/7/2021 9:08:40 AM AIkido Secures Sublicense To Technology For Targeted Psilocybin Treatment Of Neuro-Inflamed Tissue In Cancer Patients
4/5/2021 9:06:08 AM AIkido Pharma Says Sufficiently Capitalized To Support Current Efforts And To Pursue Additional Emerging Opportunities
2/19/2021 11:16:33 AM AIkido Pharma Announces Closing Of $75 Mln Bought Deal Offering Of Common Stock
2/16/2021 10:16:18 PM AIkido Pharma Increases Bought Deal Offering Of Common Stock To $75 Mln
2/16/2021 8:38:55 AM AIkido Pharma Enters Into LoI With Silo Pharma For Use Of Psilocybin And Peptide Therapy For Cancer Treatment
1/22/2021 1:44:26 PM AIkido Pharma Regains Compliance With NASDAQ Listing Requirements
1/6/2021 8:17:11 AM AIkido Pharma Executes Licensing Agreement For Psilocybin For Cancer Applications
11/20/2020 8:09:15 AM AIkido Pharma : All Stockholder Proposals Approved Other Than Authority For Reverse Stock Spilt